Full Press Release Details
SINOVAC Announces Record and Distribution Dates
for Special Cash Dividend
BEIJING - Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC"
or the "Company"), a leading provider of biopharmaceutical products in China, today announced that a special dividend
of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC's
common shares as of the close of business on May 23, 2025, ET. Such cash dividend is expected to be paid on or about July 9,
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company
that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19,
enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.
The COVID-19 vaccine, CoronaVac , has been approved
for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive , passed WHO prequalification
requirements in 2017. The EV71 vaccine, Inlive , is an innovative vaccine under "Category 1 Preventative Biological
Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella
vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza
vaccine Panflu.1 , which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company
is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu , to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more
combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive
and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please visit the Company's website at www.sinovac.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform
Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect,"
"anticipate," "aim," "estimate," "intend," "plan," "believe,"
"potential," "continue," "is/are likely to" or other similar expressions. Such statements are based
upon the Company's current expectations and current market and operating conditions and relate to events that involve known or unknown
risks, uncertainties and other factors, including without limitation risks, uncertainties and factors related to the timing and implementation
of the special dividend, all of which are difficult to predict and many of which are beyond the Company's control, which may cause
the Company's actual results, performance or achievements to differ materially from those in the forward-looking statements. Further
information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities
and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information,
future events or otherwise, except as required under law.
Sinovac Biotech Ltd.
Tel: +86-10-8279 9779
Email: ir@sinovac.com